Viracta Therapeutics Q3 FY23: net loss $12.6M; diluted EPS −$0.33

Key figures from this report

These are the numbers Viracta Therapeutics reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Net income−$12.6MAgainst −$17.7M in Q3 FY2210-Q income statement, on EDGAR
2. Diluted EPS−$0.33Against −$0.47 in Q3 FY2210-Q income statement, on EDGAR
3. Cash and cash equivalents$12.9M−45% from $23.5M in Q3 FY22Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
4. Cash from operations−$10.5MAgainst −$7.2M in Q3 FY2210-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters